AC Immune SA (NASDAQ:ACIU) Short Interest Up 24.4% in July
AC Immune SA (NASDAQ:ACIU) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 600,600 shares, an increase of 24.4% from the June 30th total of 482,900 shares. Based on an average daily volume of 112,300 shares, the short-interest ratio is presently 5.3 days. Currently, 1.9% of the shares of the company are short sold.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in AC Immune in the fourth quarter worth $6,092,000. Squarepoint Ops LLC acquired a new position in AC Immune in the fourth quarter worth $121,000. FMR LLC boosted its stake in AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock worth $53,039,000 after purchasing an additional 403,086 shares in the last quarter. Virtu Financial LLC acquired a new position in AC Immune in the first quarter worth $397,000. Finally, Alps Advisors Inc. boosted its stake in AC Immune by 4.5% in the first quarter. Alps Advisors Inc. now owns 162,707 shares of the company’s stock worth $822,000 after purchasing an additional 7,029 shares in the last quarter. Hedge funds and other institutional investors own 26.53% of the company’s stock.
A number of equities analysts have recently weighed in on the company. BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. ValuEngine upgraded AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, June 12th. Finally, HC Wainwright set a $8.00 target price on AC Immune and gave the stock a “buy” rating in a research note on Friday, July 12th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $11.94.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Wednesday, May 15th. The company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.36). AC Immune had a return on equity of 12.17% and a net margin of 29.66%. The company had revenue of $75.28 million for the quarter, compared to the consensus estimate of $106.81 million. On average, research analysts predict that AC Immune will post 0.17 earnings per share for the current fiscal year.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Story: Can systematic risk be avoided?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.